journal article·2022-02Open access

Anti-SARS-CoV-1 and −2 nanobody engineering towards avidity-inspired therapeutics

Eugene M. Obeng, Christian K.O. Dzuvor, Michael K. Danquah

Nano Today· Volume 42

Abstract

In the past two decades, the emergence of coronavirus diseases has been dire distress on both continental and global fronts and has resulted in the search for potent treatment strategies. One crucial challenge in this search is the recurrent mutations in the causative virus spike protein, which lead to viral escape issues. Among the current promising therapeutic discoveries is the use of nanobodies and nanobody-like molecules. While these nanobodies have demonstrated high-affinity interaction with the virus, the unpredictable spike mutations have warranted the need for avidity-inspired therapeutics of potent inhibitors such as nanobodies. This article discusses novel approaches for the design of anti-SARS-CoV-1 and -2 nanobodies to facilitate advanced innovations in treatment technologies. It further discusses molecular interactions and suggests multivalent protein nanotechnology and chemistry approaches to translate mere molecular affinity into avidity.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Monoclonal and Polyclonal Antibodies Research · Advanced biosensing and bioanalysis techniques · Bacteriophages and microbial interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. A systematic review of SARS-CoV-2 vaccine candidates10.1038/s41392-020-00352-y ↗
2. Coronavirus vaccine development: from SARS and MERS to COVID-19
3. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates10.1016/S0140-6736(20)32137-1 ↗
4. Neutralizing monoclonal antibodies for treatment of COVID-1910.1038/s41577-021-00542-x ↗
5. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-1910.1016/j.ymthe.2021.05.004 ↗
6. Effectiveness of convalescent plasma therapy in severe COVID-19 patients10.1073/pnas.2004168117 ↗
7. Multimerization of an alcohol dehydrogenase by fusion to a designed self-assembling protein results in enhanced bioelectrocatalytic operational stability10.1021/acsami.9b04256 ↗
8. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis10.1016/j.virusres.2014.11.021 ↗
9. The spike protein of SARS-CoV — a target for vaccine and therapeutic development10.1038/nrmicro2090 ↗
10. Emerging coronaviruses: genome structure, replication, and pathogenesis10.1002/jmv.25681 ↗
11. Proteolytic cleavage of the SARS-CoV-2 spike protein and the role of the novel S1/S2 site10.1016/j.isci.2020.101212 ↗
12. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells10.1016/j.molcel.2020.04.022 ↗
13. Site-specific glycan analysis of the SARS-CoV-2 spike10.1126/science.abb9983 ↗
14. Exploitation of glycosylation in enveloped virus pathobiology10.1016/j.bbagen.2019.05.012 ↗
15. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains10.1038/ncomms15092 ↗
16. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation10.1126/science.abb2507 ↗
17. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein10.1016/j.cell.2020.02.058 ↗
18. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma
19. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape10.1126/science.abf6950 ↗
20. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-210.1016/j.cell.2021.03.028 ↗
21. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding10.1016/j.cell.2020.08.012 ↗
22. SARS-CoV-2 variants, spike mutations and immune escape10.1038/s41579-021-00573-0 ↗
23. Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic10.1016/j.meegid.2021.104971 ↗
24. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor10.1038/s41586-020-2180-5 ↗
25. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor10.1126/science.1116480 ↗
26. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV10.1126/science.abb7269 ↗
27. Naturally occurring antibodies devoid of light chains10.1038/363446a0 ↗
28. Nanobodies and their potential applications10.2217/nnm.13.86 ↗
29. A nanoengineering approach for investigation and regulation of protein immobilization10.1021/nn800508f ↗
30. Nanobodies: natural single-domain antibodies10.1146/annurev-biochem-063011-092449 ↗
31. Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains10.1016/S0968-0004(01)01790-X ↗
32. Camelid and shark single domain antibodies: structural features and therapeutic potential
33. A case of convergence: why did a simple alternative to canonical antibodies arise in sharks and camels?10.1371/journal.pbio.1001120 ↗
34. General strategy for the generation of human antibody variable domains with increased aggregation resistance10.1073/pnas.1202866109 ↗
35. Biophysical properties of human antibody variable domains10.1016/S0022-2836(02)01237-8 ↗
36. Aggregation-resistant domain antibodies selected on phage by heat denaturation10.1038/nbt1000 ↗
37. Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering10.1021/bi9902079 ↗
38. P.S. Chowdhury, G. Vasmatzis, Engineering scFvs for Improved Stability, in: Recomb. Antibodies Cancer Ther., Humana Press, New Jersey, n.d.: pp. 237–254. doi:10.1385/1–59259-334–8:237.10.1385/1-59259-334-8:237 ↗
39. Identification of human single-domain antibodies against SARS-CoV-210.1016/j.chom.2020.04.023 ↗
40. Improving solubility and refolding efficiency of human VHs by a novel mutational approach10.1093/protein/gzl037 ↗
41. Camelized rabbit-derived VH single-domain intrabodies against vif strongly neutralize HIV-1 infectivity10.1016/j.jmb.2004.04.062 ↗
42. Crystal structure of a camel single-domain V(H) antibody fragment in complex with lysozyme10.1038/nsb0996-803 ↗
43. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies10.1093/emboj/17.13.3512 ↗
44. Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state10.1038/ncomms16165 ↗
45. Viral infection modulation and neutralization by camelid nanobodies
46. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains10.1093/protein/7.9.1129 ↗
47. Dual beneficial effect of interloop disulfide bond for single domain antibody fragments10.1074/jbc.M111.242818 ↗
48. Removal of a conserved disulfide bond does not compromise mechanical stability of a VHH antibody complex10.1021/acs.nanolett.9b02062 ↗
49. The structural basis of nanobody unfolding reversibility and thermoresistance10.1038/s41598-018-26338-z ↗
50. Single domain camel antibodies: current status10.1016/S1389-0352(01)00021-6 ↗
51. A general protocol for the generation of nanobodies for structural biology10.1038/nprot.2014.039 ↗
52. A robust pipeline for rapid production of versatile nanobody repertoires10.1038/nmeth.3170 ↗
53. Specific production rate of VHH antibody fragments by Saccharomyces cerevisiae is correlated with growth rate, independent of nutrient limitation10.1016/j.jbiotec.2005.05.010 ↗
54. Large-scale production of VHH antibody fragments by Saccharomyces cerevisiae10.1016/S0141-0229(01)00497-5 ↗
55. Increased heterologous protein production bySaccharomyces cerevisiae growing on ethanol as sole carbon source10.1002/bit.21150 ↗
56. Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection10.1128/AAC.01802-15 ↗
57. High-yield production of functional soluble single-domain antibodies in the cytoplasm of Escherichia coli10.1186/1475-2859-12-97 ↗
58. Expression and production of llama variable heavy-chain antibody fragments (VHHs) by Aspergillus awamori10.1007/s00253-004-1689-0 ↗
59. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE210.1038/s41594-020-0469-6 ↗
60. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape10.1126/science.abe6230 ↗
61. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction10.1038/s41467-020-18174-5 ↗
62. Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies10.1016/j.cell.2020.04.031 ↗
63. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike
64. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-210.1126/science.abe4747 ↗
65. Nanobody repertoires for exposing vulnerabilities of SARS-CoV-2
66. Fusion proteins for half-life extension of biologics as a strategy to make biobetters10.1007/s40259-015-0133-6 ↗
67. Conceptual approaches to modulating antibody effector functions and circulation half-life10.3389/fimmu.2019.01296 ↗
68. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo
69. Multivalent Fc γ-receptor engagement by a hexameric Fc-fusion protein triggers Fc γ-receptor internalisation and modulation of Fc γ-receptor functions10.1038/s41598-017-17255-8 ↗
70. The coming of age of engineered multivalent antibodies10.1016/j.drudis.2015.02.013 ↗
71. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design10.1002/bies.20805 ↗
72. ACE2-based decoy receptors for SARS coronavirus 2
73. Drug development of an affinity enhanced, broadly neutralizing heavy chain-only antibody that restricts SARS-CoV-2 in rodents
74. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants10.1038/s41586-021-03676-z ↗
75. Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-210.1038/s41598-020-74761-y ↗
76. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2/ACE2 interaction with high affinity and avidity10.1080/22221751.2020.1768806 ↗
77. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein10.1186/s12951-021-00768-w ↗
78. Potent neutralization of sars-cov-2 by hetero-bivalent alpaca nanobodies targeting the spike receptor-binding domain10.1128/JVI.02438-20 ↗
79. An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants
80. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants
81. Plant‐expressed Fc‐fusion protein tetravalent dengue vaccine with inherent adjuvant properties10.1111/pbi.12869 ↗
82. Polymeric human Fc-fusion proteins with modified effector functions10.1038/srep00124 ↗
83. Engineered hexavalent Fc proteins with enhanced Fc-gamma receptor avidity provide insights into immune-complex interactions10.1038/s42003-018-0149-9 ↗
84. Effect of the IgM and IgA secretory tailpieces on polymerization and secretion of IgM and IgG10.4049/jimmunol.156.8.2858 ↗
85. Multimerization is required for antigen binding activity of an engineered IgM/IgG chimeric antibody recognizing a skin-related antigen10.1038/s41598-017-08294-2 ↗
86. A polymeric immunoglobulin—antigen fusion protein strategy for enhancing vaccine immunogenicity10.1111/pbi.12932 ↗
87. Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape
88. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail10.1126/science.abd0827 ↗
89. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies10.1126/science.abd0831 ↗
90. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice10.1073/pnas.2101918118 ↗
91. Structures and distributions of SARS-CoV-2 spike proteins on intact virions10.1038/s41586-020-2665-2 ↗
92. Linker engineering in the context of synthetic protein switches and sensors10.1016/j.tibtech.2020.11.007 ↗
93. Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-210.1038/s41589-020-00679-1 ↗
94. Inhalable nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses10.1126/sciadv.abh0319 ↗
95. A bispecific monomeric nanobody induces SARS-COV-2 spike trimer dimers
96. D. Li, T. Li, H. Cai, H. Yao, B. Zhou, N. Zhang, Y. Gong, Y. Zhao, Q. Shen, W. Qin, A potent synthetic nanobody targets RBD and protects mice from SARS-CoV-2 infection, (2020).10.1101/2020.06.09.143438 ↗
97. A high-affinity RBD-targeting nanobody improves fusion partner’s potency against SARS-CoV-210.1371/journal.ppat.1009328 ↗
98. Fusion protein linkers: property, design and functionality10.1016/j.addr.2012.09.039 ↗
99. Effect of linker flexibility and length on the functionality of a cytotoxic engineered antibody fragment10.1016/j.jbiotec.2015.02.008 ↗
100. Tuning the flexibility of glycine-serine linkers to allow rational design of multidomain proteins10.1021/acs.biochem.7b00902 ↗